Abbott Responds On Meridia: Morbidity Standard Is Unworkable
Executive Summary
Weight-loss drugs such as Meridia would never come to market if approvals are based on demonstrating a reduction in morbidity and mortality, Abbott maintains
You may also be interested in...
Meridia Growth Forecast Is 50% In 2002, Despite Italian Withdrawal – Abbott
Abbott's revised forecast for the anti-obesity agent Meridia (sibutramine) still assumes a 50% increase in worldwide sales for 2002
Meridia Growth Forecast Is 50% In 2002, Despite Italian Withdrawal – Abbott
Abbott's revised forecast for the anti-obesity agent Meridia (sibutramine) still assumes a 50% increase in worldwide sales for 2002
Meridia Fatality Rate “Substantially Lower” Than Obese Population – Abbott
Abbott's Meridia patient fatality rate is "substantially lower" than what would generally be expected from the obese population, the company maintains in response to a Public Citizen Health Research Group petition calling for the drug's withdrawal